论文部分内容阅读
目的:研究小肠肿瘤患者小肠细菌过度生长(small intestinal bacterial overgrowth,SIBO)的发生情况及观察应用利福昔明治疗SIBO能否改善小肠肿瘤患者胃肠道症状.方法:采用葡萄糖氢呼气试验(glucose hydrogen breath test,GHBT)检测小肠肿瘤组28例与健康对照组30例,并对所有患者行消化系症状评分,SIBO阳性患者在原有治疗的基础上给予利福昔明治疗,疗程结束后复查GHBT,观察并记录呼气氢浓度及消化系症状评分变化情况.结果:小肠肿瘤组SIBO阳性率(57.14%)显著高于健康对照组(3.33%),差异有统计学意义(P<0.05);肿瘤组SIBO阳性患者(7.50±3.14)消化系症状积分高于SIBO阴性患者(4.00±3.22),差异有统计学意义(P<0.05).SIBO阳性患者经利福昔明治疗后复查GHBT,呼气氢浓度和消化系症状积分较治疗前均下降,差异均有统计学意义(P<0.05).结论:小肠肿瘤患者较健康人更容易发生SIBO,且SIBO可能是加重患者消化系症状的原因之一.应用利福昔明治疗SIBO后,患者消化系症状改善,一定程度上提高了患者的生活质量.
Objective: To study the incidence of small intestinal bacterial overgrowth (SIBO) in patients with small intestine tumor and to observe whether application of rifaximin can improve gastrointestinal symptoms in patients with small bowel cancer.Methods: Glucose hydrogen breath test glucose hydrogen breath test (GHBT)), 28 cases of small intestine tumor and 30 cases of healthy control group, all patients were given digestive symptom score, SIBO-positive patients were treated with rifaximin on the basis of the original treatment, GHBT were observed and recorded.Results: The positive rate of SIBO in small intestine tumor group (57.14%) was significantly higher than that in healthy control group (3.33%), the difference was statistically significant (P <0.05) (7.50 ± 3.14) were higher than those in SIBO-negative patients (4.00 ± 3.22), the difference was statistically significant (P <0.05) .SIBO-positive patients were treated with rifaximin after the review of GHBT, The expiratory hydrogen concentration and digestive system symptom scores decreased compared with those before treatment, and the differences were statistically significant (P <0.05) .Conclusion: SIBO is more likely to occur in patients with small bowel cancer than in healthy people, and SIBO may aggravate the digestion One reason for the symptoms. Rifaximin treatment applications SIBO, digestive symptoms improve and enhance the quality of life of patients to some extent.